OMICS Group International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS Group hosts over 400 leading-edge peer reviewed Open Access Journals and organizes over 300 International Conferences annually all over the world. OMICS Publishing Group journals have over 3 million readers and the fame and success of the same can be attributed to the strong editorial board which contains over 30000 eminent personalities that ensure a rapid, quality and quick review process. OMICS Group signed an agreement with more than 1000 International Societies to make healthcare information Open Access.
OMICS Group welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best possible way. OMICS Journals are poised in excellence by publishing high quality research. OMICS Group follows an Editorial Manager® System peer review process and boasts of a strong and active editorial board.

Editors and reviewers are experts in their field and provide anonymous, unbiased and detailed reviews of all submissions. The journal gives the options of multiple language translations for all the articles and all archived articles are available in HTML, XML, PDF and audio formats. Also, all the published articles are archived in repositories and indexing services like DOAJ, CAS, Google Scholar, Scientific Commons, Index Copernicus, EBSCO, HINARI and GALE.

For more details please visit our website: http://omicsonline.org/Submitmanuscript.php
EDITOR
Claudette Klein, PhD
Professor
Biochemistry and Molecular Biology
RESEARCH INTEREST

We propose that the novel use of Zn as a chemotherapeutic agent for cancer will significantly improve patient outcome. We are using prostate cancer and ovarian cancer tissue culture cells to test the generally applicability of Zn as a cancer treatment. Our research involves evaluating varied means by which we can selectively deliver cytotoxic levels of Zn to cancer cells while sparing non-targeted cells. Additionally, we are investigating the mechanism by which Zn kills cancer cells with the idea of indentifying new pathways and/or targets for additional drug development.
PUBLICATIONS


• Zinc induces ERK-dependent cell death through a specific Ras isoform. Claudette Klein, Kimberly Creach, Virginia Irintcheva, Katherine J Hughes, Penny Lane Blackwell, John A Corbett, Joseph J Baldassare Apoptosis 2006 Nov;11(11):1933-44
INTRODUCTION

• The ovaries are a pair of small organs in the female reproductive system that contain and release an egg once a month. This is known as ovulation. Cancer of the ovary can spread to other parts of the reproductive system and the surrounding areas, including the womb (uterus), vagina and abdomen.
What Is Ovarian Cancer?

• Ovarian cancer is a malignancy of the ovaries, the female sex organs that produce eggs and make the hormones estrogen and progesterone. Treatments for ovarian cancer are improving, and the best outcomes are always seen when the cancer is found early.
How common is ovarian cancer?

• Cancer of the ovary affects over 315 women in Ireland each year. It is the fifth most common cancer among women after breast cancer, bowel cancer, lung cancer and cancer of the uterus (womb). Ovarian cancer is most common in women who have had the menopause (usually over the age of 55), but it can affect women of any age.
TYPES

• **epithelial ovarian cancer**, which affects the surface layers of the ovary; it is by far the most common type

• **germ cell tumours**, which originate in the cells that make the eggs

• **stromal tumours**, which develops within the cells that hold the ovaries together
SIGNS and SYMPTOMS

• The symptoms of ovarian cancer can be difficult to recognise, particularly in the early stages of the disease. They are often the same as the symptoms of other, less serious, conditions, such as irritable bowel syndrome (IBS) or pre-menstrual syndrome (PMS). The three symptoms are:
  • persistent pelvic and abdominal pain
  • increased abdominal size/persistent bloating (not bloating that comes and goes)
  • difficulty eating and feeling full quickly, or feeling nauseous
CAUSES

• Family history
• If you have two or more close relatives (mother, sister or daughter) who developed ovarian cancer or breast cancer, you may be at higher risk of developing the condition.
• If your relatives developed cancer before the age of 50, it may be the result of an inherited faulty gene. Faulty genes that have been linked to ovarian cancer include BRCA1 and BRCA2. They are also known to be linked to the development of breast cancer.
• Age

• Your risk of ovarian cancer increases with age. Most cases of ovarian cancer occur after the menopause, in women who are over 65 years old.

• **Hormone replacement therapy (HRT)**

• Women who take hormone replacement therapy (HRT) have been shown to have a small increased risk of ovarian cancer. However, if HRT is stopped, after five years the risk goes back down to the same risk as women who have never taken HRT.
PREVENTION

• **Stopping ovulation and the contraceptive pill**

• Each time you ovulate, your ovaries are damaged by an egg breaking through and being released into your reproductive system. The cells that make up the surface of your ovaries divide and multiply rapidly in order to repair the damage caused by the egg. It is this rapid cell growth that can occasionally go wrong and result in ovarian cancer.
• Therefore, anything that stops the process of ovulation can help to minimise your chances of developing ovarian cancer. Factors that stop ovulation temporarily or altogether include:
  • pregnancy and breastfeeding
  • the contraceptive pill
  • hysterectomy surgery (removal of the ovaries)
Diet and lifestyle

• Research into ovarian cancer has found that the condition may be linked to being overweight or obese. Losing weight through exercise, and having a balanced diet, may help to lower your risk of ovarian cancer. Aside from this, it is known that regular exercise and a healthy, low-fat diet are extremely beneficial to your overall health, and can help to prevent all forms of cancer and heart disease.
• **Blood test (CA125)**

• You may have a blood test to look for a chemical called CA125 in the blood. This chemical is produced by some ovarian cancer cells and a raised level of CA125 in the blood may mean you have ovarian cancer.

• However, a significant proportion of women with early stage ovarian cancers have a normal CA125 level. The chemical is also produced by other conditions and a raised level of CA125 does not definitely mean you
• **Ultrasound**

• Ultrasound uses high frequency sound waves to produce an image of your ovaries. You may have an internal ultrasound (known as a transvaginal ultrasound), where the ultrasound probe is inserted into your vagina. Or you may have an external ultrasound, where the probe is put next to your stomach. The image produced can show the size and texture of your ovaries, as well as any cysts that may be present.
THANK YOU
OMICS publishing Group Open Access Membership enables academic and research institutions, funders and corporations to actively encourage open access in scholarly communication and the dissemination of research published by their authors. For more details and benefits, click on the link below:

http://omicsonline.org/membership.php